10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2026)

10x Genomics has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $6.6 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities rose 7.04% year-over-year to $6.6 million; the TTM figure through Jun 2026 stood at $6.6 million (up 7.04% YoY), while the FY2025 annual figure was $6.5 million, up 28.67% from the prior year.
• Other Non-Current Liabilities came in at $6.6 million for Q2 2026 at 10x Genomics, up from $6.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $10.1 million in Q3 2023 to a low of $3.0 million in Q4 2022.
• Average Other Non-Current Liabilities over 5 years is $6.2 million, with a median of $6.3 million recorded in 2025.
• Year-over-year, Other Non-Current Liabilities slumped 63.88% in 2022 and jumped 77.04% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $3.0 million in 2022, then surged by 43.65% to $4.3 million in 2023, then climbed by 17.64% to $5.0 million in 2024, then advanced by 28.67% to $6.5 million in 2025, then increased by 1.31% to $6.6 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $6.6 million in Q2 2026, $6.4 million in Q1 2026, and $6.5 million in Q4 2025.